Related Experiment Video
Updated: May 19, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Aflibercept in pediatric solid tumors: moving beyond the trap.
1Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Summary
Angiogenesis inhibitors show promise for childhood cancers, with aflibercept offering a proof-of-principle. Further research is needed to establish effective clinical endpoints and biomarkers for pediatric trials.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis is crucial for solid tumor growth and metastasis in both adults and children.
- Targeting angiogenesis is a key strategy in cancer therapy.
Purpose of the Study:
- To review the role of angiogenesis inhibitors in pediatric oncology.
- To highlight the potential and challenges of developing these therapies for childhood cancers.
Main Methods:
- Review of current clinical investigations and pediatric trials of angiogenesis inhibitors.
- Analysis of the proof-of-principle study involving aflibercept in pediatric patients.
Main Results:
- Clinical trials investigating angiogenesis inhibitors for pediatric solid tumors are ongoing.
- The pediatric study of aflibercept demonstrates the feasibility of targeting angiogenesis in children.
Conclusions:
- While promising, developing effective clinical endpoints and reliable biomarkers for angiogenesis inhibition in pediatric trials remains a significant challenge.
- Further research is essential to optimize the use of angiogenesis inhibitors in treating childhood cancers.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...